| 货号 | 10008640-1ea |
| 描述 | The Cayman Asthma Treatment Standard Set contains three potent, selective Cysteinyl Leukotriene (CysLT) 1 receptor antagonists (10 mg each) currently used clinically for the treatment of asthma. Zafirlukast and Montelukast (sodium salt), sold under the trade names Accolate and Singulair, respectively, are used for the treatment of asthma as well as for the symptoms associated with allergic rhinitis.1,2,3 Pranlukast, sold under the trade name Ultair, was the first CysLT receptor antagonist marketed for the treatment of asthma.4,5 In addition to these three CysLT1 receptor antagonists, the asthma pak also includes Zileuton, which is supplied free of charge. Zileuton is a reversible 5-LO inhibitor that was approved in 1997 for the prevention and treatment of asthma in the USA, but was withdrawn by Abbott Laboratories in 2003.6,7 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Matassa, V.G.,Maduskuie, T.P., Jr.,Shapiro, H.S., et al. Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles. Journal of Medicinal Chemistry 33, 1781-1790 (1990). 2.Silverman, R.A.,Nowak, R.M.,Korenblat, P.E., et al. Zafirlukast treatment for acute asthma. Evaluation in a randomized, double-blind, multicenter trail. Chest 126, 1480-1489 (2004). 3.Peters-Golden, M., and Henderson, W.R. The role of leukotrienes in allergic rhinitis. Ann. Allergy Asthma Immunol. 94(6), 609-618 (2005). 4.Barnes, N.C.,de Jong, B., and Miyamoto, T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 111, 52-60 (1997). 5.Taniguchi, Y.,Tamura, G.,Honma, M., et al. The effect of an oral leukotriene antagonist ONO-1078, on allergen-induced immediate bronchoconstriction. Journal of Allergy and Clinical Immunology 92, 507-512 (1993). 6.Carter, G.W.,Young, P.R.,Albert, D.H., et al. 5-Lipoxygenase inhibitory activity of zileuton. Journal of Pharmacology and Experimental Therapeutics 256, 929-937 (1991). 7.Zouboulis, C.C.,Saborowski, A., and Boschnakow, A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 210, 36-38 (2005). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |